Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ATXS Astria Therapeutics, Inc. Common Stock
$12.44 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ATXS stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 710.1M
Enterprise value 583.9M
Trailing PE -7.4047616549901
Forward PE -5.2895017
PEG Ratio -0.23923076116122
Enterprise to EBITDA -5.2341378655049
Enterprise to revenue 827.068
Price to book MRQ 5.1022916
Price to sales TTM 1008.28326

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 706.0K
Diluted EPS TTM -2.14
Total Cash (MRQ) 227.7M
Current ratio (MRQ) 10.781
Operating Cash Flow (TTM) -119733000

ATXS trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ATXS News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.